Abstract
Microdosing, or human phase 0 clinical trials, is a technique whereby subpharmacological doses of prospective drug candidates are administered to human volunteers. A microdose study provides early pharmacokinetic data in humans and only requires minimal preclinical toxicology safety testing. A microdose is defined as 100th of the pharmacological dose (or predicted pharmacological dose) or a maximum of 100µg. Microdosing is a relatively recent innovation and there remains a degree of uncertainty as to whether such a small dose will adequately predict the pharmacokinetics of the therapeutically active dose. Notwithstanding this, in situations when traditional methods such as in vitro and laboratory animal models prove to be unreliable, microdosing can offer the supporting and alternative data on which to select suitable drug candidates for development, prior to commencing expensive full phase I clinical trials.
The current published data on microdosing is somewhat sparse, although there have been a few papers in recent times. This paper is the first compressive review of the microdosing concept since the publication of the US Food and Drug Administration exploratory IND study guidance in January 2006, which covers the preclinical requirements to enable a microdose study in humans to take place.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003; 2 (3): 233–40
EMEA. Position paper on non-clinical safety studies to support clinical trials with a single microdose. Position paper: CPMP/SWP/2599. 2004 Jun [online]. Available from URL: http://www.emea.eu.int/pdfs/human/swp/259902en.pdf [Accessed 2006 Jun 22]
Food and Drug Administration, US Department of Health and Human Services. Guidance for industry investigators and reviewers: exploratory IND studies. 2006 Jan. [online]. Available from URL: http://www.fda.gov [Accessed 2006 Jun 22]
Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 2004; 58 (6): 601–8
Timchalk C. Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids: evidence that the dog is not a relevant species for evaluation of human health risk. Toxicology 2004; 200 (1): 1–19
Balani SK, Nagaraja NV, Qian MG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006; 34 (3): 384–8
Lappin G, Garner RC. Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. In: Wilson I, editor. Handbook of analytical separations. Amsterdam: Elsevier, 2003: 331–49
Lappin G, Temple S. Radiotracers in drug development. Boca Raton (FL): Taylor and Francis, 2006
Lappin GJ, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with five drugs. Clin Pharmacol Ther. In press
ICH Topic M3: Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals: ICH step 5. Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. CPMP/ICH/286/95 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ich/028695en.pdf [Accessed 2006 Jun 20]
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22 (2): 151–85
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3 (8): 711–5
Kennedy T. Managing the drug discovery/development interface. Drug Discov Today 1997; 2: 436–44
Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37 (1): 1–16
MacGowan AP. Role of pharmacokinetics and pharmacodynamics: does the dose matter? Clin Infect Dis 2001; 33 Suppl. 3: S238–9
Kautiainen A, Vogel JS, Turteltaub KW. Dose-dependent binding of trichloroethylene to hepatic DNA and protein at low doses in mice. Chem Biol Interact 1997; 106 (2): 109–21
Frantz CE, Bangerter C, Fultz E, et al. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis 1995; 16 (2): 367–73
Turteltaub KW, Felton JS, Gledhill BL, et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci U S A 1990; 87 (14): 5288–92
Mauthe RJ, Dingley KH, Leveson SH, et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int J Cancer 1999; 80 (4): 539–45
Turteltaub KW, Mauthe RJ, Dingley KH, et al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res 1997; 376 (1–2): 243–52
Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003; 59 (5–6): 357–66
Sandhu P, Vogel JS, Rose MJ, et al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 2004; 32 (11): 1254–9
Brunton LL, Lazo JS, Parker KL. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006
Levy G, Mager DE, Cheung WK, et al. Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 2003; 92 (5): 985–94
Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16 (6): 337–64
Thummel KE, O’Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59 (5): 491–502
Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002; 87 (3): 277–80
Beumer JH, Beijnen JH, Schellens JH. Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 2006; 45 (1): 33–58
Pons G, Rey E. Stable isotopes labeling of drugs in pediatric clinical pharmacology. Pediatrics 1999; 104 (3 Pt 2): 633–9
Acknowledgements
Professor Colin Garner is Chief Executive Officer and Dr Graham Lappin is Head of Research at Xceleron Ltd; both hold minority stakes in the company.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lappin, G., Garner, R.C. A Review of Human Phase 0 (Microdosing) Clinical Trials Following the US Food and Drug Administration Exploratory Investigational New Drug Studies Guidance. Int J Pharm Med 20, 159–165 (2006). https://doi.org/10.2165/00124363-200620030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00124363-200620030-00002